https://ir.edwards.com/overview/default.aspx
WEBCorporate Overview. Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as …
DA: 46 PA: 96 MOZ Rank: 21
https://www.edwards.com/newsroom/news/2022-12-08-edwards-lifesciences-outlines-growth-strategy-at-a
WEBDec 8, 2022 · Projecting 2023 TMTT sales of $160 - $200 million. Estimating 2023 adjusted earnings per share of $2.45 - $2.60. Focused long-term growth …
DA: 24 PA: 30 MOZ Rank: 40
https://www.edwards.com/gb/newsroom/news/2021-12-08-edwards-lifesciences-outlines-growth-strategy-at-a-6a405fd
WEBDec 8, 2021 · Highlights of today's conference include: Reaffirming October 2021 financial guidance. Projecting 2022 global sales of $5.5 - $6.0 billion; …
DA: 81 PA: 97 MOZ Rank: 53
https://www.edwards.com/newsroom/news/2023-12-07-edwards-lifesciences-outlines-growth-strategy-at-a-cebe112
WEBDec 7, 2023 · The Edwards Lifesciences 2023 investor conference can be accessed via live webcast at ir.edwards.com beginning at 8:30 a.m. …
DA: 37 PA: 25 MOZ Rank: 24
https://www.edwards.com/newsroom/news/2022-04-26-edwards-lifesciences-reports-first-quarter-results-2c02e60
WEBMar 31, 2022 · IRVINE, Calif., April 26, 2022-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2022. First …
DA: 11 PA: 48 MOZ Rank: 88